A blood-based metabolomics test to distinguish relapsing–remitting and secondary progressive multiple sclerosis: addressing practical considerations for clinical application by Yeo, T, Sealey, M, Zhou, Y, Saldana, L, Loveless, S, Claridge, TDW, Robertson, N, DeLuca, G, Palace, J, Anthony, DC, Probert, F

Classifying the antibody-negative NMO syndromes: Clinical, imaging, and metabolomic modeling by Yeo, T, Probert, F, Jurynczyk, M, Sealey, M, Cavey, A, Claridge, TDW, Woodhall, M, Waters, P, Leite, MI, Anthony, DC, Palace, J

Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model by Yeo, T, Bayuangga, H, Augusto-Oliveira, M, Sealey, M, Claridge, TDW, Tanner, RL, Leppert, D, Palace, J, Kuhle, J, Probert, F, Anthony, DC

Integrative biochemical, proteomics and metabolomics cerebrospinal fluid biomarkers predict clinical conversion to multiple sclerosis by Probert, F, Yeo, T, Zhou, Y, Sealey, M, Arora, S, Palace, J, Claridge, TDW, Hillenbrand, R, Oechtering, J, Leppert, D, Kuhle, J, Anthony, DC

Objective biomarkers for clinical relapse in multiple sclerosis: a metabolomics approach by Yeo, T, Probert, F, Sealey, M, Saldana, L, Geraldes, R, Höeckner, S, Schiffer, E, Claridge, TDW, Leppert, D, DeLuca, G, Kuhle, J, Palace, J, Anthony, DC

Metabolomic biomarkers in blood samples identify cancers in a mixed population of patients with nonspecific symptoms by Larkin, JR, Anthony, S, Johanssen, VA, Yeo, T, Sealey, M, Yates, AG, Smith, CF, Claridge, TDW, Nicholson, BD, Moreland, J-A, Gleeson, F, Sibson, NR, Anthony, DC, Probert, F